Skip to Content

BioMerieux SA BMXMF

Rating as of

Morningstar’s Analysis

Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price


5-Star Price


Economic Moat


About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Company Profile

Business Description

BioMerieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (40% of 2020 sales), microbiology (30%), immunoassays (15%), and industrial applications (about 15%). North America accounts for the largest portion of the firm's revenue (45%), followed by Europe, the Middle East, and Africa (33%), Asia-Pacific (16%), and Latin America (6%). BioMerieux is headquartered in Marcy-l'Etoile, France.

Marcy l’Etoile
Lyon, 69280, France
T +33 478872000
Sector Healthcare
Industry Diagnostics & Research
Most Recent Earnings
Fiscal Year End Dec 31, 2019
Stock Type
Employees 12,800